Endocyte (ECYT) Tops Q1 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Endocyte Reports First Quarter 2016 Financial Results
May 4, 2016 8:03 AM EDT- Data from Phase 1 Dose Escalation Studies of EC1456 and EC1169 to be Presented at ASCO -
- Expansion Phase of Trials in Targeted Patients Expected to Yield Efficacy Data in 2016Â -
- Promising Preclinical Data Demonstrates Unique SMDC Applications in Immuno-Oncology -
      - Conference Call Today at 8:30 a.m. EDT
WEST LAFAYETTE, Ind., May 04, 2016 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ: ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for... More
